These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29511346)

  • 1. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.
    Reebye V; Huang KW; Lin V; Jarvis S; Cutilas P; Dorman S; Ciriello S; Andrikakou P; Voutila J; Saetrom P; Mintz PJ; Reccia I; Rossi JJ; Huber H; Habib R; Kostomitsopoulos N; Blakey DC; Habib NA
    Oncogene; 2018 Jun; 37(24):3216-3228. PubMed ID: 29511346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
    Sarker D; Plummer R; Meyer T; Sodergren MH; Basu B; Chee CE; Huang KW; Palmer DH; Ma YT; Evans TRJ; Spalding DRC; Pai M; Sharma R; Pinato DJ; Spicer J; Hunter S; Kwatra V; Nicholls JP; Collin D; Nutbrown R; Glenny H; Fairbairn S; Reebye V; Voutila J; Dorman S; Andrikakou P; Lloyd P; Felstead S; Vasara J; Habib R; Wood C; Saetrom P; Huber HE; Blakey DC; Rossi JJ; Habib N
    Clin Cancer Res; 2020 Aug; 26(15):3936-3946. PubMed ID: 32357963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.
    Setten RL; Lightfoot HL; Habib NA; Rossi JJ
    Curr Pharm Biotechnol; 2018; 19(8):611-621. PubMed ID: 29886828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.
    Voutila J; Reebye V; Roberts TC; Protopapa P; Andrikakou P; Blakey DC; Habib R; Huber H; Saetrom P; Rossi JJ; Habib NA
    Mol Ther; 2017 Dec; 25(12):2705-2714. PubMed ID: 28882451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma.
    Zhao X; Reebye V; Hitchen P; Fan J; Jiang H; Sætrom P; Rossi J; Habib NA; Huang KW
    Oncogene; 2019 May; 38(18):3446-3457. PubMed ID: 30643190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models.
    Huang KW; Tan CP; Reebye V; Chee CE; Zacharoulis D; Habib R; Blakey DC; Rossi JJ; Habib N; Sodergren MH
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.
    Zhou J; Li H; Xia X; Herrera A; Pollock N; Reebye V; Sodergren MH; Dorman S; Littman BH; Doogan D; Huang KW; Habib R; Blakey D; Habib NA; Rossi JJ
    Mol Ther; 2019 May; 27(5):999-1016. PubMed ID: 30852139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
    Hashimoto A; Sarker D; Reebye V; Jarvis S; Sodergren MH; Kossenkov A; Sanseviero E; Raulf N; Vasara J; Andrikakou P; Meyer T; Huang KW; Plummer R; Chee CE; Spalding D; Pai M; Khan S; Pinato DJ; Sharma R; Basu B; Palmer D; Ma YT; Evans J; Habib R; Martirosyan A; Elasri N; Reynaud A; Rossi JJ; Cobbold M; Habib NA; Gabrilovich DI
    Clin Cancer Res; 2021 Nov; 27(21):5961-5978. PubMed ID: 34407972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo.
    Reebye V; Sætrom P; Mintz PJ; Huang KW; Swiderski P; Peng L; Liu C; Liu X; Lindkaer-Jensen S; Zacharoulis D; Kostomitsopoulos N; Kasahara N; Nicholls JP; Jiao LR; Pai M; Spalding DR; Mizandari M; Chikovani T; Emara MM; Haoudi A; Tomalia DA; Rossi JJ; Habib NA
    Hepatology; 2014 Jan; 59(1):216-27. PubMed ID: 23929703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA Activation-A Novel Approach to Therapeutically Upregulate Gene Transcription.
    Tan CP; Sinigaglia L; Gomez V; Nicholls J; Habib NA
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Liver Cancer by C/EBPA saRNA.
    Zhao X; Voutila J; Ghobrial S; Habib NA; Reebye V
    Adv Exp Med Biol; 2017; 983():189-194. PubMed ID: 28639200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted delivery of CEBPA-saRNA for the treatment of pancreatic ductal adenocarcinoma by transferrin receptor aptamer decorated tetrahedral framework nucleic acid.
    Wang L; Yao Q; Guo X; Wang B; Si J; Wang X; Jing S; Yan M; Shi Y; Song G; Shen X; Guan J; Zhao Y; Zhu C
    J Nanobiotechnology; 2024 Jul; 22(1):392. PubMed ID: 38965606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentially expressed MicroRNAs provide mechanistic insight into fibrosis-associated liver carcinogenesis in mice.
    Marrone AK; Shpyleva S; Chappell G; Tryndyak V; Uehara T; Tsuchiya M; Beland FA; Rusyn I; Pogribny IP
    Mol Carcinog; 2016 May; 55(5):808-17. PubMed ID: 25865624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
    Haberl EM; Pohl R; Rein-Fischboeck L; Feder S; Sinal CJ; Buechler C
    Anticancer Res; 2018 May; 38(5):2649-2657. PubMed ID: 29715085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression.
    Yan T; Yan N; Xia Y; Sawaswong V; Zhu X; Dias HB; Aibara D; Takahashi S; Hamada K; Saito Y; Li G; Liu H; Yan H; Velenosi TJ; Krausz KW; Huang J; Kimura S; Rotman Y; Qu A; Hao H; Gonzalez FJ
    J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of steatohepatitis, fibrosis, and carcinogenesis in mice fed a methionine-choline deficient diet by CCAAT/enhancer-binding protein homologous protein deficiency.
    Toriguchi K; Hatano E; Tanabe K; Takemoto K; Nakamura K; Koyama Y; Seo S; Taura K; Uemoto S
    J Gastroenterol Hepatol; 2014 May; 29(5):1109-18. PubMed ID: 24329600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.
    Wu K; Ding J; Chen C; Sun W; Ning BF; Wen W; Huang L; Han T; Yang W; Wang C; Li Z; Wu MC; Feng GS; Xie WF; Wang HY
    Hepatology; 2012 Dec; 56(6):2255-67. PubMed ID: 22898879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation.
    Lu GD; Leung CH; Yan B; Tan CM; Low SY; Aung MO; Salto-Tellez M; Lim SG; Hooi SC
    Gastroenterology; 2010 Aug; 139(2):632-43, 643.e1-4. PubMed ID: 20347819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
    Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
    J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma.
    Qian C; Idoate M; Bilbao R; Sangro B; Bruña O; Vázquez J; Prieto J
    Hum Gene Ther; 1997 Feb; 8(3):349-58. PubMed ID: 9048202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.